Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
From the literature given, we are not in a position to yet say PCSK9 inhibitors do reduce cardiovascular events to any clinical certainty, and within any form of long term measure.
There is much anticipation of positive results for this drug class. There remains a risk that an extrapolation of their effects of LDL cholesterol, is used as a justification for their adoption in secondary prevention.
The headline for this article states that the new drugs described reduce cardiovascular events. The subsequent article makes no reference to these findings, merely that the drugs were shown to reduce measured LDL levels.